Core Viewpoint - Gongdong Medical (605369) has announced a significant decline in its expected net profit for 2025, forecasting a drop of 67.37% to 74.36% year-on-year, with net profit projected between 44 million to 56 million yuan [4]. Financial Performance - The expected non-recurring net profit for 2025 is estimated to be between 54 million to 66 million yuan, reflecting a year-on-year decrease of 60.75% to 67.89% [4]. - As of January 23, the company's price-to-earnings ratio (TTM) is approximately 77.37 to 98.47 times, with a price-to-book ratio (LF) of about 2.52 times and a price-to-sales ratio (TTM) of around 3.85 times [4]. Reasons for Performance Decline - The decline in performance is attributed to several factors: 1. **Goodwill Impairment**: The company has recognized signs of impairment related to goodwill from its acquisition of Trademark Plastics Inc. (TPI), with an estimated impairment amount between 24 million to 30 million yuan due to TPI's operational challenges influenced by international trade policies and shipping cost fluctuations [13]. 2. **Gross Margin Decrease**: The gross margin has been affected by the slowdown in demand for certain products due to U.S. tariff policies and domestic medical procurement policies [14]. 3. **Exchange Rate Fluctuations**: Financial expenses related to exchange rate fluctuations have significantly reduced, contributing to the decline in net profit. Additionally, losses from investments in a controlled entity have impacted non-operating income by approximately 11 million yuan [15].

Core Viewpoint - Gongdong Medical (605369) is expected to report a significant decline in net profit for 2025, with projections ranging from 44 million to 56 million yuan, representing a year-on-year decrease of 67.37% to 74.36% [2] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of 44 million to 56 million yuan for 2025 [2] - This forecast indicates a substantial decline in profitability compared to the previous year, with a decrease of 67.37% to 74.36% [2] Group 2: Operational Challenges - The decline in performance is attributed to the operating results of its subsidiary, Trademark Plastics Inc. (TPI), which have been negatively impacted by international trade policies and fluctuations in shipping costs [2] - Additionally, the company faces challenges from U.S. tariff policies and domestic medical "group purchasing" policies, leading to a slowdown in demand for some of its products [2]

拱东医疗（605369）(605369.SH)发布2025年年度业绩预告，预计公司2025年度实现归属于母公司所有 者的净利润为4,400万元到5,600万元，与上年同期相比，将减少11,563.28万元到12,763.28万元，同比减 少67.37%到74.36%。 ...

智通财经APP讯，拱东医疗(605369.SH)发布2025年年度业绩预告，预计公司2025年度实现归属于母公 司所有者的净利润为4,400万元到5,600万元，与上年同期相比，将减少11,563.28万元到12,763.28万元， 同比减少67.37%到74.36%。 ...

Core Viewpoint - The company, Gongdong Medical (605369.SH), anticipates a significant decline in net profit for the fiscal year 2025, with projections indicating a decrease of 67.37% to 74.36% compared to the previous year [1] Financial Projections - The expected net profit attributable to the parent company's owners for 2025 is estimated to be between 44 million to 56 million yuan [1] - The projected net profit, excluding non-recurring gains and losses, is forecasted to be between 54 million to 66 million yuan, reflecting a year-on-year decrease of 60.75% to 67.89% [1] Business Impact - The company's business has been adversely affected by the U.S. tariff policies and domestic medical "collection" policies, leading to a slowdown in demand for certain products [1] - As a result of the aforementioned factors, the gross profit margin for related business segments has experienced a decline [1]

Core Viewpoint - Gongdong Medical (605369) expects a significant decline in net profit for 2025, projecting a range of 44 million to 56 million yuan, which represents a year-on-year decrease of 67.37% to 74.36% [1] Group 1: Financial Performance - The company anticipates a net profit attributable to the parent company of 44 million to 56 million yuan for 2025 [1] - This projected profit decline is attributed to various factors, including international trade policies and fluctuations in shipping costs affecting the performance of its subsidiary, Trademark Plastics Inc. (TPI) [1] Group 2: Market Conditions - The company is facing challenges due to the impact of U.S. tariff policies and domestic medical "group purchasing" policies, which have led to a slowdown in demand growth for some of its products [1]

1、本期业绩预告适用于：实现盈利，且净利润与上年同期相比下降 50%以 上的情形。 证券代码：605369 证券简称：拱东医疗 公告编号：2026-001 浙江拱东医疗器械股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （一）利润总额：18,873.52 万元。归属于母公司所有者的净利润：17,163.28 万元。归属于母公司所有者的扣除非经常性损益的净利润：16,814.95 万元。 （二）每股收益：1.09 元。 2、经浙江拱东医疗器械股份有限公司（以下简称"公司"）财务部门初步测 算，预计公司 2025 年度实现归属于母公司所有者的净利润为 4,400.00 万元到 5,600.00 万元，与上年同期相比，将减少 11,563.28 万元到 12,763.28 万元，同比 减少 67.37%到 74.36%。 3、预计公司 2025 年度实现归属于母公司所有者的扣除非经常性损益的净利 润 5,400.00 万元到 6,600.00 万元，与上年同期相比，将减少 10 ...

拱东医疗公告，预计2025年度实现归属于母公司所有者的净利润为4400万元到5600万元，与上年同期相 比，将减少1.16亿元到1.28亿元，同比减少67.37%到74.36%。预计实现归属于母公司所有者的扣除非经 常性损益的净利润5400万元到6600万元，与上年同期相比，将减少1.02亿元到1.14亿元，同比减少 60.75%到67.89%。本期业绩预减的主要原因为商誉减值、毛利率下降及汇率波动。 ...

Core Viewpoint - Gongdong Medical (605369) has implemented a "Quality Improvement and Efficiency Enhancement" action plan aimed at upgrading its core business and enhancing investor returns, which includes measures in R&D, production, market expansion, and dividend policies [1] Company Announcement Summary - Gongdong Medical's stock closed at 18.81 yuan on December 26, 2025, reflecting a 1.46% increase from the previous week's closing price of 18.54 yuan [1] - The stock reached a peak price of 19.4 yuan on December 25, 2025, and a low of 18.06 yuan on December 23, 2025 [1] - The company's current total market capitalization is 4.147 billion yuan, ranking 84th out of 127 in the medical device sector and 3839th out of 5178 in the A-share market [1] - The "Quality Improvement and Efficiency Enhancement" action plan includes increased R&D investment, promotion of intelligent production, expansion into domestic and international markets, improvement of corporate governance, enhanced information disclosure, and implementation of stable dividends [1] - The plan aims to protect investor rights but does not constitute a substantive commitment to investors, indicating inherent uncertainties [1]

Core Viewpoint - The company has announced a "Quality Improvement and Efficiency Enhancement Action Plan" aimed at enhancing its core competitiveness and operational quality in the medical device industry, while also focusing on investor returns and protection of minority shareholders' rights [1][10]. Group 1: Business Focus and Operational Quality - The company is a leading player in the domestic medical device industry, with a strong focus on R&D, production, and sales of disposable medical consumables, laboratory consumables, and medical polymer products [1]. - In 2024, the company achieved a revenue of 1,115.21 million yuan, a year-on-year increase of 14.37%, and a net profit attributable to shareholders of 171.63 million yuan, up 57.28% from the previous year [2]. - Future strategies include enhancing R&D investment, focusing on high-end medical consumables and biopharmaceutical laboratory consumables, and optimizing production processes to improve capacity utilization and product quality [2]. Group 2: Governance and Compliance - The company has established a modern governance structure in compliance with relevant laws and regulations, ensuring clear division of responsibilities among shareholders, the board, and management [3]. - In 2024, the company revised several internal regulations to enhance governance and internal control systems, improving operational efficiency and compliance [4]. Group 3: Investor Relations and Information Disclosure - The company adheres to strict information disclosure standards, ensuring transparency and timely communication of strategic initiatives and operational results to investors [5]. - Future plans include enhancing the effectiveness of information disclosure, focusing on key investor concerns, and expanding communication channels with the capital market [6]. Group 4: Investor Returns - The company emphasizes reasonable returns for investors, with a cumulative cash dividend of 233.68 million yuan over the last three fiscal years, representing a cash dividend ratio of 115.53% [7]. - In 2024, the total amount for cash dividends and buybacks was 145.81 million yuan, accounting for 84.95% of the net profit attributable to shareholders, reflecting the company's commitment to shareholder returns [7]. Group 5: Management of Key Personnel - The company prioritizes the management of key personnel, including major shareholders and executives, through training and compliance awareness initiatives [8]. - Future efforts will focus on enhancing the performance evaluation and incentive mechanisms for key personnel, aligning their interests with the long-term goals of the company [8].